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Abstract
Purpose Thyrotropin receptor (TSHR) autoantibodies (TRAbs) are a hallmark of Graves’ disease (GD). The aim of this 
study was to evaluate the diagnostic accuracy of a new third generation automatic fluorescence enzyme immunoassay for 
TRAb measurement in GD, in comparison with two current IMAs.
Methods Sera of 439 subjects (57 patients with untreated GD, 34 with treated GD, 15 with GD and Graves’ orbitopathy, 52 
with multinodular non-toxic goiter, 86 with Hashimoto’s thyroiditis, 20 with toxic adenoma or toxic multinodular goiter, 55 
with non-thyroid autoimmune diseases and 120 normal controls) were tested for TRAbs with the  ELiA™ anti-TSH-R assay 
(ThermoFischer Scientific, Uppsala, Sweden), the  TRAK™ RIA, Brahms (Thermo Scientific, Hennigsdorf, Germany) and 
the  Immulite™ TSI assay (Siemens Healthcare, Llanberis, UK).
Results Sensitivity and specificity of the ELiA™ anti-TSH-R assay, TRAK™ RIA and Immulite™ TSI assay were 94.7% 
and 99.6, 100 and 98.2%, 100 and 98.2%, respectively. Spearman’s coefficient and Passing-Bablok regression showed a sat-
isfactory correlation between EliA™ and TRAK™ [rho: 0.925; 95% CI: 0.883-0-953. Intercept: − 0.875 (95% CI: − 2.411 
to 0.194); slope: 1.086 (95% CI: 0.941 to 1.248)], and between  ELiA™ and  TSI™ [rho: 0.947; 95% CI: 0.912 0.969. intercept: 
1.085 (95% CI: 0.665 to 2.116); slope 1.315 (95% CI:1.116 to 1.700)].
Conclusions The diagnostic performance of  ELiA™-TSH-R assay is comparable to that of some current TRAb assays. It may 
be adopted into clinical practice for the differential diagnosis of hyperthyroidism, to screen for transient hyperthyroidism, 
and to monitor disease activity and treatment effects.
Keywords Thyrotropin receptor autoantibodies (TRAbs) · Graves’ disease (GD) · Immunometric assays · ELiA™ anti-
TSH-R assay
Introduction
The thyrotropin receptor (TSHR), expressed on the cell 
surface of thyrocytes, initiates the major signals that direct 
thyroid cell growth and hormone synthesis/secretion [1]. In 
addition, it is now well-established that TSHR is expressed 
in a variety of extra-thyroidal cells, including fibroblasts, 
adipocytes and bone cells, where it is known to modulate 
target cell function [2, 3]. The TSHR is a target autoantigen 
in Graves’ disease (GD) [4–6], where TSHR autoantibodies 
(TRAbs) induce thyroid growth and hyperthyroidism and 
represent an important diagnostic hallmark. TRAbs are also 
detected in a small portion of patients with Hashimoto’s thy-
roiditis (HT) [5].
Three varieties of TRAb are recognized: stimulating 
(S-TRAbs), blocking (B-TRAbs), and “neutral” (neutral 
TRAbs) autoantibodies. Some authors report that S-TRAbs 
preferentially recognize the N-terminal region, while 
B-TRAbs are more biased toward the C-terminal region 
of the ectodomain of the TSHR [7, 8]. Neutral TRAbs are 
reported to be directed against the cleavage region of the 
TSHR and are able to induce apoptosis in thyrocytes [9]. 
However, experimental evidence, including the analysis 
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of the crystal structure of the TSHR extracellular domain 
bound to stimulating or blocking human monoclonal autoan-
tibodies, show that TRAbs bind extensively across the leu-
cine rich repeats of the TSHR extracellular domain, regard-
less of biological activity [10]. TRAbs without stimulating 
activity can be enriched from normal individuals [11].
In the last 50 years, bioassay (BA) and immunoassay 
(IMA) methods have been used to detect autoantibod-
ies against the TSHR. BAs measure functional activity of 
TRAbs, (S-TRAbs, B-TRAbs), while IMAs measure the 
binding of autoantibodies to the receptor (total TRAbs, 
T-TRAbs) and are not able to differentiate S-TRAbs from 
B-TRAbs [12]. Since S-TRAbs are highly correlated with 
GD activity, BAs result as the optimal method for TRAb 
detection in GD. They are, however, cumbersome, time-
consuming and in need of optimization and standardiza-
tion [13], thus it remains restricted to a limited number of 
specialized laboratories. On the contrary, second and third 
generation IMAs are suitable for clinical practice and show 
high analytical and clinical accuracy [14, 15], even if they 
do not allow to distinguish between the different kinds of 
TRAbs found in patients with AITDs. However, recently, an 
assay using chimeric TSHR putatively detecting S-TRAbs, 
based on the putative structure of the extracellular domain 
of the TSHR and its interaction with TSHR antibodies [1], 
has been developed [16].
The aim of this study was to evaluate the diagnostic 
accuracy of a new third generation automatic fluorescence 
enzyme immunoassay (FEIA) for TRAb measurement in 
GD, in comparison with the current two IMAs.
Materials and methods
Patients
Sera of 439 subjects [57 patients with untreated GD, 34 with 
treated GD (1–12 months of treatment), 15 with GD and 
Graves’ orbitopathy (GD/GO), 52 with non-toxic multinodu-
lar goiter (NTMG), 86 with HT, 20 with toxic adenoma or 
toxic multinodular goiter (TA/TMG), 55 with non-thyroid 
autoimmune diseases (NTAD) (systemic lupus erythemato-
sus, rheumatoid arthritis, autoimmune gastritis, celiac dis-
ease), and 120 normal controls (NC)] were evaluated. GD 
subjects were diagnosed according to the American Thyroid 
Association-American Association of Clinical Endocrinolo-
gists guidelines [17].
Patients affected by HT were selected according to the 
following criteria: ultrasound hypoechogenicity and if the 
thyroperoxidase antibodies (TPOAbs) levels were higher 
than the upper reference limit. NC (60 males and 60 females) 
were screened during the “Thyroid takes to the square” sur-
vey, carried out in the province of Verona (Italy) from 2008 
to 2013. These subjects met the NACB criteria: younger than 
30 years, TSH between 0.5 and 2.0 mIU/L, normal thyroid 
ultrasound, absence of autoimmune and non-autoimmune 
thyroid disease or other autoimmune diseases [18]. All of 
them gave informed consent for their participation in the 
study.
Immunoassays
The  ELiA™ anti-TSH-R assay is a competitive fully auto-
mated fluoroenzyme immunoassay (ThermoFischer Scien-
tific, Uppsala, Sweden). The design of the method is as fol-
lows: a human recombinant TSH receptor is immobilized via 
capture antibody to the well; TRAbs in the patient’s sample 
(90 μL diluted 1:2 with PBS containing BSA, EDTA, deter-
gent and sodium azide 0.095%) bind to the coated human 
receptor (sample incubation at 37 °C for 30 min); after wash-
ing away unbound components, 90 μL of β-galactosidase-
labeled mouse recombinant antibodies (ELiA™ anti-TSH-
R Conjugate) are added to form a TSH receptor-conjugate 
complex with TSH receptors not blocked by serum antibod-
ies. After incubation at 37 °C for 30 min and washing away 
the unbound conjugate, 90 μL of a development solution 
(0.01% 4-methylumbelliferyl-β-d-galactoside) is added and 
the fluorescence activity is measured. The Phadia 250 instru-
ment (ThermoFischer Scientific) automatically processes all 
steps of the test.
ELiA™ anti-TSH-R assay uses a 6-point calibration curve 
(0–40 IU/L), and is calibrated against the 2nd International 
Standard (IS) NIBSC 08/204. The cut-off suggested by the 
manufacturer was 3.3 IU/L.
The results obtained with the  ELiA™ anti-TSH-R assay 
were compared with those obtained with the  TRAK™ 
Human radio-immunoassay (TRAb RIA, Brahms Termo 
Scientific, Henningsdorf, Germany), a second generation 
immunoassay [9], and with the  Immulite™ TSI assay (Sie-
mens Heathcare, Llanberis, UK).
TRAK™ is a manual radio-immunoassay. In the first step, 
100 μL of patient’s serum was incubated for 2 h at room tem-
perature in a tube coated with human TSH receptor. After 
washing, 200 μL of  I125 labeled TSH was added. Labeled 
TSH binds to the remaining unoccupied TSH receptors. 
After incubation for 1 h at room temperature and after the 
discharge of the free labeled TSH, the tube is counted in 
a gamma counter. The content of TRAbs in the patient’s 
sample is inversely proportional to the bound labeled TSH.
Immulite™ TSI assay is a fully automated chemilumines-
cent IMA, designed to detect S-TRAbs. It employs a pair of 
recombinant human TSHR constructs in a bridging format: 
the capture and the signal receptor [16]. The capture con-
struct is a TSHR chimera with the N-terminus of human 
TSHR binding the S-TRAbs, and LH/CG epitope replacing 
the residues 261–370 putatively binding the B-TRAb. The 
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signal receptor is constructed from a portion of the extracel-
lular domain (aa 21-26) of TSHR. It is fused with secretory 
alkaline phosphatase (SEAP) in a buffer solution. Briefly, 
in the first step, 50 μL of patient’s serum is incubated with 
the solid phase (polystyrene bead) for 30 min, allowing the 
TRAbs in the sample to bind through one arm of the cap-
ture receptor. After washing, the signal receptor is added to 
the reaction tube and incubated for 30 min. Unbound signal 
receptor is then removed by centrifugal washes, chemilumi-
nescent substrate is added to the reaction tube and a signal 
is generated in direct relation to the amount of TRAbs in 
the sample.
The cut-off levels suggested by the manufactures were 
1.5 IU/L and 0.55 IU/L for TRAK and TSI, respectively.
TRAK was calibrated against 1st IS (NIBSC 90/672) and 
TSI  Immulite™ against 2nd IS (NIBSC 08/204).
Statistical evaluation
Statistical analysis was performed by MedCalc software 
version 10.4.5 (Mariakerke, Belgium) and GraphPad Prism, 
Version 4.0 (San Diego, CA, USA). A two-sided value of 
p < 0.05 was considered statistically significant.
TRAb values lower than the limit of quantification (LoQ) 
were considered equal to LoQ for statistical purpose. The 
normality of TRAb distribution was assessed using the Sha-
piro–Wilk test for the results of each assay. As serum TRAb 
values were not normally distributed, TRAb values were 
described as median with range (minimum–maximum) and 
the statistical analyses were performed using non-parametric 
tests, in particular the Kruskal-Wallis test to compare the 
NC group with the others (GD, GDT, OB, NTMG, NC, AT, 
NATD).
Receiver operating characteristic (ROC) curve for 
ELiA™ anti-TSH-R assay was plotted and analyzed to select 
the best cut-off level. Clinical sensitivity and specificity were 
also calculated [19].
Correlation, linear association and agreement between 
assays were assessed by Spearman’s Rank Correlation 
Coefficient (rho), Passing-Bablok regression analyses and 
Bland–Altman plots, respectively. The qualitative (posi-
tive/negative) agreement between  ELiA™ anti-TSH-R assay 
and the other methods was evaluated by means of Cohen’s 
Kappa.
Results
According to the ROC curve analysis, the optimal threshold 
to maximize sensitivity and specificity of the ELiA™ anti-
TSH-R assay was 3.8 IU/L (Fig. 1), slightly higher than that 
suggested by the manufacturer. Using this cut-off, the sensi-
tivity for untreated GD was 94.7% and the specificity 99.6%. 
The percentage of TRAb positivity in all patient groups is 
shown in Fig. 2, and the median and range (minimum–maxi-
mum) values of the TRAbs for each group are reported in 
Table 1. A statistically significant difference (p < 0.0001) 
was shown between the TRAb levels of NC and those of the 
GD and GD/GO groups. Values of TRAbs of the treated GD 
group were significantly lower than those of the untreated 
GD and GD/GO groups (p < 0.01).
Using the TRAK™ and the TSI™ assay, the sensitivity 
and specificity were 100 and 98.2%, and 100 and 98.2%, 
respectively. The overall agreement, evaluated using a 2 × 2 
classification table, between  ELiA™ and  TRAK™ was 97.9% 
(CI 95%: 96.1–99.0) [positive agreement: 95.3% (CI 95%: 
92.2–99.5), negative agreement 98.7% (CI 95%: 97.8–99.5)]; 
Cohen k: 0.940 (CI 95%: 0.90–0.98). The overall agreement 
between ELiA™ and TSI™ was 98.5% (CI 95%: 92.0–98.0) 
Fig. 1  ROC analysis for  ELiA™ TRAb assay
Fig. 2  ELiA-TRAb levels in the different groups enrolled in the study. 
u-GD, Graves’ disease before the treatment, t-GD GD on treatment, 
GD/GO Graves’ patients with orbitopathy, NTMG multinodular non-
toxic goiter, TA/TMG toxic adenoma/toxic multinodular goiter, HT 
Hashimoto’s thyroiditis; NTAD non-thyroid autoimmune diseases, NC 
normal controls, % positive cases, c.o cut-off
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[positive agreement: 96.3% (CI 95%: 93.6–99.0), negative 
agreement: 99.1% (98.4–99.8)]; Cohen k: 0.954 (CI 95%: 
0.92–0.98).
Spearman’s coefficient and Passing-Bablok regres-
sion showed a satisfactory correlation between  EliA™ and 
 TRAK™ (Fig. 3a) [rho: 0.925; 95% CI: 0.883–0.953. Inter-
cept: − 0.875 (95% CI: − 2.411 to 0.194); slope: 1.086 (95% 
CI: 0.941 to 1.248)], and between  ELiA™ and  TSI™ (Fig. 3b) 
[rho: 0.947; 95% CI: 0.912 0.969. intercept: 1.085 (95% CI: 
0.665 to 2.116); slope 1.315 (95% CI:1.116 to 1.700)].
Bland–Altman analysis between ELiA™ and TRAK 
pointed out a bias of − 0.3 IU/L (95% CI: − 10 to +9.4) 
(Fig. 4a), and between  ELiA™ and  TSI™, a bias of 4.2 IU/L 
(95% CI: − 13.8 to +22.1) (Fig. 4b), showing an acceptable 
agreement.
Table 1  Median and range of the  EliA™ TRAb values in different 
groups of patients
u-GD Graves’ disease before treatment, t-GD GD on treatment, GD/
GO Graves’ patients with orbitopathy, NTMG multinodular non-toxic 
goiter, TA/TMG toxic adenoma/toxic multinodular goiter, HT Hashi-
moto’s thyroiditis, NTAD non-thyroid autoimmune diseases, NC nor-
mal controls








u-GD 57 10.0 0.7− > 50 < 0.0001
t-GD 34 5.95 1.6− > 50 < 0.0001
GD/GO 15 16.3 2.2− > 50 < 0.0001
NTMG 52 1.4 0.6–2.3 ns
TA/TMG 20 1.3 1.0–3.3 ns
HT 86 1.1 0.1–2.7 ns
NTAD 55 2.2 1.0–4.4 ns
NC 120 1.4 0.7–3.8 ns
Overall 439
Fig. 3  Correlation between  ELIA™ TRAb assay and  TRAK™ Assay (a), and between  ELIA™ TRAb assay and  TSI™ Immulite (b) (Passing-
Bablok analyses)
Fig. 4  Inter-assay agreement between  ELIA™ TRAb assay and TRAK™ Assay (a), and between  ELIA™ TRAb assay and TSI™ Immulite 
(Bland–Altman plots)
Autoimmunity Highlights (2018) 9:3 
1 3
Page 5 of 6 3
Discussion
TRAb detection is widely accepted as a routine test for 
diagnosing and monitoring GD and for differential diag-
nosis of the various forms of hyperthyroidism [20]. In this 
study, we evaluated the diagnostic accuracy of the new 
fully automated third generation assay  (ELiA™-TSH-R 
assay) for the measurement of TRAbs in comparison with 
the two current IMAs.
The diagnostic sensitivity of  ELiA™-TSH-R assay 
for GD resulted high, though slightly lower than those 
of the  TRAK™ and  TSI™ Immulite assays. In all prob-
ability, this is associated to the lower analytical sensi-
tivity of the  ELiA™-TSH-R assay, as shown by the high 
cut-off (3.8 IU/L). However, the three patients negative 
with  ELiA™-TSH-R assay resulted low positive with 
the other two assays. On the contrary, the specificity of 
 ELiA™-TSH-R assay (99.6%) was slightly higher than 
those of  TRAK™ and TSI™ Immulite assays (98.2%). 
In the control population, only one patient with sys-
temic lupus erythematosus (SLE) showed a low titer of 
TRAbs (4.4 IU/L). It is not surprising, since SLE is the 
autoimmune disease associated with the largest number 
of autoantibodies [21]. Thyroid antibodies, in particular, 
are frequently associated with this autoimmune disease 
and are predictive markers of thyroid disorders (hypothy-
roidism and hyperthyroidism), present in SLE with a high 
prevalence [22]. No patients with HT showed positivity for 
TRAbs with the  ELiA™-TSH-R assay, whereas three cases 
resulted positive with the other two methods. In the case of 
 TSI™ Immulite, putatively measuring only S-TRAbs, this 
result was unexpected, but confirmed the findings of other 
studies [15, 22]. The absence of TRAbs in HT with the 
 ELiA™-TSH-R assay was also surprising, since previous 
studies using second and third generation assays detected 
TRAbs in 5–20% of HT patients [14, 24–26], putatively 
B-TRAbs or neutral TRAbs. We cannot discriminate 
whether this represents a higher specificity of the method 
(i.e., no/low detection of B-TRAbs or neutral TRAbs) or a 
lower sensitivity, since positive samples obtained with the 
other two methods were not tested with a BA.
As expected, patients undergoing anti-thyroid drug 
treatment for 1–12 months showed lower TRAb values, 
with 24% resulting as negative. The majority of negative 
patients (7/8) were in clinical remission or euthyroid while 
on long-term low dose anti-thyroid drugs, confirming the 
usefulness of TRAb measurement for following disease 
activity and treatment effects [7, 23].
Correlation and agreement between  ELiA™-TSH-R 
assay and the other methods were good, even if it was 
higher with the  TRAK™ assay, notwithstanding the lat-
ter is calibrated against the first international standard 
(NIBSC code 90/672). This is likely due to the differ-
ent designs of the  TSI™ Immulite assays, as previously 
described.
In conclusion, the diagnostic performance of the fully 
automated 3rd generation  ELiA™-TSH-R assay is at least 
comparable to that of some current TRAb assays, with a 
trend toward a higher specificity. As a consequence, it may 
be adopted into clinical practice for the differential diagnosis 
of hyperthyroidism (including patients with unusual GD/
GO), to screen for transient hyperthyroidism, and to monitor 
disease activity and treatment effects.
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